| Next 10 |
Ad
AUPH News and Press Aurinia Pharmaceuticals Inc
News | Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
-
2023-09-21 06:54:43 ET More on Aurinia Seeking Alpha’s Quant Rating on Aurinia Pharma Historical earnings data for Aurinia Pharma Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders Aurinia spikes on Q2 earnings beat, guidance raise ...
-
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, “MKT Capital”...
-
2023-09-18 14:18:23 ET Aurinia Pharmaceuticals (NASDAQ: AUPH) , a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The stock has recovered some of its losses since hitting this intraday low, but it...
-
Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that...
-
2023-08-03 12:32:02 ET Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Conference Call August 3, 2023, 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Con...
-
2023-08-03 06:40:52 ET More on Aurinia Pharma Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over Aurinia...
-
2023-08-03 06:02:12 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11 . Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M . Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ...
-
Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ® (voclosporin) Conference call to be hosted today at 8:30 a.m...
-
2023-08-02 13:39:36 ET Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus Revenue Estimate is $37.51M (+33.0% Y/Y). Over the last ...
-
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:3...
Stock Information
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Ad
-
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, “MKT Capital”...
-
2023-09-18 14:18:23 ET Aurinia Pharmaceuticals (NASDAQ: AUPH) , a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The stock has recovered some of its losses since hitting this intraday low, but it...
-
Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that...